JP2015512949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512949A5 JP2015512949A5 JP2015505963A JP2015505963A JP2015512949A5 JP 2015512949 A5 JP2015512949 A5 JP 2015512949A5 JP 2015505963 A JP2015505963 A JP 2015505963A JP 2015505963 A JP2015505963 A JP 2015505963A JP 2015512949 A5 JP2015512949 A5 JP 2015512949A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- composition
- diabetes
- cholesterol
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624087P | 2012-04-13 | 2012-04-13 | |
| US61/624,087 | 2012-04-13 | ||
| PCT/US2013/036484 WO2013155485A2 (en) | 2012-04-13 | 2013-04-12 | Method of using cyclodextrin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018150978A Division JP2018203747A (ja) | 2012-04-13 | 2018-08-10 | シクロデキストリンを使用するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512949A JP2015512949A (ja) | 2015-04-30 |
| JP2015512949A5 true JP2015512949A5 (https=) | 2016-06-09 |
| JP6491089B2 JP6491089B2 (ja) | 2019-03-27 |
Family
ID=49328287
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505963A Active JP6491089B2 (ja) | 2012-04-13 | 2013-04-12 | シクロデキストリンを使用するための方法 |
| JP2018150978A Pending JP2018203747A (ja) | 2012-04-13 | 2018-08-10 | シクロデキストリンを使用するための方法 |
| JP2021103893A Pending JP2021155436A (ja) | 2012-04-13 | 2021-06-23 | シクロデキストリンを使用するための方法 |
| JP2023146755A Pending JP2023178518A (ja) | 2012-04-13 | 2023-09-11 | シクロデキストリンを使用するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018150978A Pending JP2018203747A (ja) | 2012-04-13 | 2018-08-10 | シクロデキストリンを使用するための方法 |
| JP2021103893A Pending JP2021155436A (ja) | 2012-04-13 | 2021-06-23 | シクロデキストリンを使用するための方法 |
| JP2023146755A Pending JP2023178518A (ja) | 2012-04-13 | 2023-09-11 | シクロデキストリンを使用するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10195227B2 (https=) |
| EP (2) | EP4299121A3 (https=) |
| JP (4) | JP6491089B2 (https=) |
| CN (2) | CN111419870A (https=) |
| CA (1) | CA2870316C (https=) |
| ES (1) | ES2959119T3 (https=) |
| MX (2) | MX371073B (https=) |
| WO (1) | WO2013155485A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX371073B (es) * | 2012-04-13 | 2020-01-15 | L&F Res Llc | Método para utilizar ciclodextrina. |
| CN111973484A (zh) | 2013-03-12 | 2020-11-24 | 普莱玛疗法公司 | 包含螯合剂和碱的牙用组合物 |
| JP6418911B2 (ja) * | 2014-11-18 | 2018-11-07 | 学校法人中部大学 | Ｇｌｐ−１分泌促進剤 |
| JP2018517046A (ja) | 2015-06-10 | 2018-06-28 | ビテス， インコーポレイテッド | ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法 |
| CN105395549A (zh) * | 2015-11-03 | 2016-03-16 | 天津医科大学总医院 | 烟酸的新用途 |
| EP3515501A1 (en) * | 2016-09-19 | 2019-07-31 | Aten Porus Lifesciences | Cyclodextrin based polymers, methods, compositions and applications thereof |
| WO2018075622A1 (en) * | 2016-10-19 | 2018-04-26 | University Of Miami | Materials and methods for modulating insulin signaling and preserving podocyte function |
| CN107982546A (zh) * | 2017-12-05 | 2018-05-04 | 中国药科大学 | 基于主客体相互作用的酸敏感超分子纳米粒及其应用 |
| BR112021008139A2 (pt) | 2018-10-29 | 2021-08-03 | Cyclo Therapeutics, Inc. | métodos para tratar doença de alzheimer |
| CN113490691A (zh) | 2019-01-03 | 2021-10-08 | 劣势者药物有限公司 | 环糊精二聚体、其组合物及其用途 |
| WO2020213010A1 (en) * | 2019-04-16 | 2020-10-22 | Celagenex Research (India) Pvt. Ltd. | Synergistic lipid controlling compositions |
| WO2021096998A1 (en) * | 2019-11-11 | 2021-05-20 | Atsuo Ochi | Method and a kit to reprogram somatic cells |
| US12226431B2 (en) | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| US20240000826A1 (en) * | 2020-08-27 | 2024-01-04 | Beren Therapeutics P.B.C. | Methods for the treatment of cardiovascular disease with cyclodextrins |
| MX2023002420A (es) * | 2020-08-27 | 2023-07-11 | Beren Therapeutics P B C | Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas. |
| KR20230096975A (ko) * | 2020-08-27 | 2023-06-30 | 베렌 테라퓨틱스 피.비.씨. | 사이클로덱스트린을 이용한 콜레스테롤 결정 색전증 치료 방법 |
| CN112089843B (zh) * | 2020-10-13 | 2022-11-04 | 合肥工业大学 | 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用 |
| JP2024509376A (ja) * | 2021-02-18 | 2024-03-01 | ベレン セラピューティクス ピー．ビー．シー． | 家族性ヘテロ接合型及びホモ接合型高コレステロール血症のシクロデキストリンによる治療方法 |
| CN113295793B (zh) * | 2021-05-20 | 2022-11-04 | 复旦大学附属中山医院 | 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用 |
| CN116322710A (zh) * | 2021-09-01 | 2023-06-23 | 株式会社雷纳图斯 | 包括γ-环糊精聚合物的药物组合物以及其用途 |
| WO2023156966A1 (en) | 2022-02-18 | 2023-08-24 | Beren Therapeutics P.B.C. | Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0672100B2 (ja) * | 1989-11-15 | 1994-09-14 | 株式会社上野製薬応用研究所 | 利尿剤 |
| US5840713A (en) * | 1995-04-03 | 1998-11-24 | Weisz; Paul B. | Therapy for tissue membrane insufficiency |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| US6756504B2 (en) | 2000-04-19 | 2004-06-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
| US20040121983A1 (en) * | 2002-08-12 | 2004-06-24 | Council Of Scientific And Industrial Research | Method for treating leishmaniasis using methyl-beta-cyclodextrin |
| PL220776B1 (pl) | 2002-08-19 | 2016-01-29 | Soho Flordis Internat Pty Ltd | Zastosowanie α-cyklodekstryny do wytwarzania leku do zmniejszania biegunki |
| JP2004323443A (ja) * | 2003-04-25 | 2004-11-18 | Tokai Univ | 抗血栓薬 |
| WO2005000217A2 (en) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
| US9200245B2 (en) | 2003-06-26 | 2015-12-01 | Seng Enterprises Ltd. | Multiwell plate |
| US7393826B2 (en) * | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| US7276351B2 (en) | 2003-09-10 | 2007-10-02 | Seahorse Bioscience | Method and device for measuring multiple physiological properties of cells |
| US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
| CN1282425C (zh) * | 2004-06-22 | 2006-11-01 | 王美岭 | 苹果醋营养品及其生产方法 |
| US20060128653A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of decitabine |
| JP2006191830A (ja) * | 2005-01-12 | 2006-07-27 | Unitika Ltd | 脂肪の蓄積を抑制する食品 |
| AU2006208108A1 (en) | 2005-01-27 | 2006-08-03 | Erimos Pharmaceuticals Llc | Oral formulations for delivery of catecholic butanes including NDGA compounds |
| WO2007056435A2 (en) | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
| US20090324624A1 (en) | 2006-06-16 | 2009-12-31 | Florida Atlantic University | Chitin micro-particles as an adjuvant |
| EP1894924A1 (en) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| WO2008067027A2 (en) * | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
| EP1920785A1 (en) * | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| WO2010042202A1 (en) | 2008-10-07 | 2010-04-15 | Fibrogen, Inc. | Methods for treatment of podocyte injury |
| CN102438614A (zh) * | 2008-10-10 | 2012-05-02 | 利默里克生物制药公司 | 用于治疗的吡喃酮类似物 |
| US8202702B2 (en) | 2008-10-14 | 2012-06-19 | Seahorse Bioscience | Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision |
| US8263413B1 (en) | 2008-10-17 | 2012-09-11 | Andrew S Hansen | Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry |
| EP2352502A4 (en) | 2008-11-06 | 2012-12-26 | Univ Miami | LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF NURSE DISEASE |
| WO2010103823A1 (ja) | 2009-03-12 | 2010-09-16 | パナソニック株式会社 | 画像表示装置および画像表示方法 |
| US8975241B2 (en) * | 2009-10-08 | 2015-03-10 | Song Ho Biomed Co., Ltd. | Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component |
| WO2011057172A1 (en) | 2009-11-06 | 2011-05-12 | University Of Miami | Podocyte specific assays and uses thereof |
| US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| EP2595623B1 (en) | 2010-07-19 | 2018-02-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Use of delta tocopherol for the treatment of lysosomal storage disorders |
| WO2012054321A2 (en) * | 2010-10-19 | 2012-04-26 | University Of Miami | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
| MX371073B (es) * | 2012-04-13 | 2020-01-15 | L&F Res Llc | Método para utilizar ciclodextrina. |
-
2013
- 2013-04-12 MX MX2014012200A patent/MX371073B/es active IP Right Grant
- 2013-04-12 CA CA2870316A patent/CA2870316C/en active Active
- 2013-04-12 US US14/391,236 patent/US10195227B2/en active Active
- 2013-04-12 EP EP23183457.3A patent/EP4299121A3/en active Pending
- 2013-04-12 EP EP13775223.4A patent/EP2836221B1/en active Active
- 2013-04-12 WO PCT/US2013/036484 patent/WO2013155485A2/en not_active Ceased
- 2013-04-12 CN CN202010200900.6A patent/CN111419870A/zh active Pending
- 2013-04-12 MX MX2020000205A patent/MX392972B/es unknown
- 2013-04-12 ES ES13775223T patent/ES2959119T3/es active Active
- 2013-04-12 JP JP2015505963A patent/JP6491089B2/ja active Active
- 2013-04-12 CN CN201380019867.5A patent/CN104244956B/zh active Active
-
2018
- 2018-08-10 JP JP2018150978A patent/JP2018203747A/ja active Pending
- 2018-12-20 US US16/227,018 patent/US10980828B2/en active Active
-
2021
- 2021-01-22 US US17/155,545 patent/US20210228616A1/en not_active Abandoned
- 2021-06-23 JP JP2021103893A patent/JP2021155436A/ja active Pending
-
2022
- 2022-09-21 US US17/949,672 patent/US20230338412A1/en not_active Abandoned
-
2023
- 2023-09-11 JP JP2023146755A patent/JP2023178518A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512949A5 (https=) | ||
| Ma et al. | Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels | |
| CN103717219B (zh) | 左心室舒张功能改善剂 | |
| US20240358718A1 (en) | Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors | |
| JP5302900B2 (ja) | 脂肪性肝疾患の治療用医薬組成物 | |
| Siddiqui et al. | Ranolazine: a review of its use in chronic stable angina pectoris | |
| AU2014259352B2 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| JP2011512347A5 (https=) | ||
| CN110022877B (zh) | 用于治疗非酒精性脂肪性肝病的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮 | |
| Parfianowicz et al. | Finerenone: a new era for mineralocorticoid receptor antagonism and cardiorenal protection | |
| ES2525748T3 (es) | Agente terapéutico o profiláctico para la diabetes | |
| EP3956021A1 (en) | Methods of treating hypertension with activators of tie-2 | |
| JP7758655B2 (ja) | 組合せ | |
| WO2014036603A1 (en) | Uses of (-)-perhexiline | |
| JP7569492B2 (ja) | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 | |
| JP2025513240A5 (https=) | ||
| WO2023026247A1 (en) | Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea | |
| CN113350338A (zh) | 用于抗血小板凝集同时合并其它疾病治疗的药物组合物及其应用 | |
| Pleasants | Medication safety in chronic lung disease with cardiac comorbidity | |
| JP4433496B2 (ja) | Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用 | |
| EP2552436A1 (en) | Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide | |
| JPH11189537A (ja) | プロスタグランジン類の医薬用途 | |
| AU782001B2 (en) | Methods for treating cardiogenic shock using a nitric oxide synthase inhibitor | |
| JP2010520854A (ja) | 高コレステロール血症の治療又は予防において使用するためのニトロキシド | |
| WO2012057343A1 (ja) | Ｎａｄ（ｐ）ｈオキシダーゼ阻害剤、酸化ストレス疾患治療薬、酸化ストレス疾患治療方法及びスクリーニング方法 |